Olitigaltin is under clinical development by Galecto and currently in Phase III for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase III drugs for Idiopathic Pulmonary Fibrosis have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Olitigaltin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olitigaltin overview

Olitigaltin (GB-0139) is under development for the treatment of idiopathic pulmonary fibrosis and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is formulated as an inhalable powder via dry powder inhaler. It acts by targeting galectin-3.

Galecto overview

Galecto is a drug development company. It focuses on the development of galectin modulators for the treatment of cancer, fibrosis and inflammation. The company develops activators and inhibitors of galectins. Its pipeline products include GB0139 to treat

For a complete picture of Olitigaltin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.